Kerry becomes biotech leader

KERRY Group has become a bio-science company of world standing following its €355 million acquisition of Quest from ICI, Davy Stockbrokers believe.

In a detailed research note on Kerry Group Davy Stockbroker's food analyst John O'Reilly argues that the purchase of Quest adds a whole new pharma dimension to Kerry Group.

Mr O'Reilly believes the acquisition of Quest's food ingredients business from ICI marks a significant point of departure in Kerry's strategy.